Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00729365 · ClinicalTrials.gov registry record · Phase 3
PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)
A Phase 3 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 65
- Enrollment target
NCT00729365 is a Phase 3 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 65 participants.
The verdict
NCT00729365, a Phase 3 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 65 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the early treatment with a blood pressure medication (an ACE Inhibitor) can prevent or delay the development of kidney disease (microalbuminuria) in patients with Type 1 diabetes who have normal blood pressure and urine albumin levels.
Interventions
- DRUG Placebo
- DRUG Ramipril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2008-07 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00729365
The ClinicalTrials.gov registry entry for NCT00729365 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00729365 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00729365 about?
NCT00729365 is a clinical study titled "PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)". The purpose of this study is to determine if the early treatment with a blood pressure medication (an ACE Inhibitor) can prevent or delay the development of kidney disease (microalbuminuria) in patients with Type 1 diabetes who have normal blood pressure and urine albumin levels.
What is the current status of trial NCT00729365?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 65 participants. The study started on 2008-07. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00729365?
The interventions under investigation include: Placebo (DRUG), Ramipril (DRUG).
Who is sponsoring clinical trial NCT00729365?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.